Virginia is currently home to 1822 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Sleep Extension to Improve Sleep Efficiency and QoL in HF With Preserved Ejection Fraction: the SLEEP-HF Pilot Study
NCT06567925
Recruiting
Nearly one-third of US adults have poor sleep quality. Sleep quality refers to sleep efficiency, sleep latency, sleep duration, wake after sleep onset, and movement during the night. Specifically, sleep efficiency (SE) measures how well an individual utilizes their time in bed for restorative sleep and it highly depends on actual sleep duration. Reduced SE is associated with a greater risk for heart failure (HF), which affects \~6.7 million adults in the US alone. HF with preserved ejection frac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Heart Failure With Preserved Ejection Fraction
Register for Updates
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults with Refractory or Unexplained Chronic Cough
NCT06504446
Recruiting
This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/21/2025
Locations: TPMG Clinical Research Williamsburg, Williamsburg, Virginia
Conditions: Refractory or Unexplained Chronic Cough
Register for Updates
Anti-Inflammatory Lifestyle Intervention for Emerging Adult Cancer Survivors
NCT06442397
Recruiting
To test the feasibility and acceptability of AILI and associated research procedures among emerging adult cancer survivors (EACS, N=16) age 18-29.
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, School of Medicine, Richmond, Virginia
Conditions: Survivorship
Register for Updates
A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer
NCT06395753
Recruiting
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Urology of Virginia, Virginia Beach, Virginia
Conditions: Prostate Cancer
Register for Updates
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
NCT06370000
Recruiting
Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Acute Myeloid Leukemia
Register for Updates
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty
NCT06129539
Recruiting
The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52 weeks after the first Debio 4326 injection in pediatric participants receiving gonadotropin-releasing hormone agonist (GnRHa) therapy for central precocious puberty (CPP).
Gender:
ALL
Ages:
Between 5 years and 8 years
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University Health System, Richmond, Virginia
Conditions: Central Precocious Puberty
Register for Updates
Health Education Approach to Lung Screening
NCT06070870
Recruiting
Evaluate the impact of the patient navigation program on the proportion of patients who complete lung cancer screening (LCS), defined as undergoing a low dose computed tomography (LDCT)
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Lung Cancer
Register for Updates
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
NCT05703971
Recruiting
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Cancer Specialists, PC, Fairfax, Virginia
Conditions: Small Cell Lung Cancer Extensive Stage
Register for Updates
A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
NCT05653882
Recruiting
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth, Richmond, Virginia
Conditions: Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Register for Updates
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
NCT05556824
Recruiting
This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/21/2025
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Gastroesophageal Reflux
Register for Updates
Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years with Insomnia Disorder
NCT05423717
Recruiting
This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to \< 18 years with insomnia disorder.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
02/21/2025
Locations: National Clinical Research, Inc, Richmond, Virginia
Conditions: Insomnia
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Oncology Associates,744 N. Battlefield Blvd, Chesapeake, Virginia
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates